Neuropathology of Alzheimer's disease and mild cognitive impairment;Neuropatología de la enfermedad de Alzheimer y del deterioro cognitivo leve

Revista de Neurologia

Volumn 37, Issue 2, 2003, Pages 155-163

  López, Óscar L ^a   DeKosky, S T ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Alzheimer's disease; Mild cognitive impairment; Neuropathology

Indexed keywords

ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; CLINICAL EXAMINATION; COGNITIVE DEFECT; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; LEWY BODY; MEYNERT BASAL NUCLEUS; NEUROPATHOLOGY; SENILE PLAQUE;

EID: 0041563673     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3702.2002441     Document Type: Conference Paper

References (142)

1. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998; 51: 728-33.
2. Corrada M, Brookmeyer R, Kawas C. Sources of variability in prevalence rates of Alzheimer's disease. Int J Epidemiol 1998; 24: 1000-5.
3. Evans DA, Funkenstein HH, Alberts MS. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA 1989; 262: 2551-6.
4. Hyman BT, Van Hoesen GW, Damasio AR. Alzheimer's disease: cell specific pathology isolates the hippocampal formation. Science 1984; 225: 1168-70.
5. Hyman BT, Van Hoesen GW, Kromer LJ, et al. Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol 1986; 20: 472-81.
6. Hof PR, Bierer LM, Perl DP, et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile placques. Arch Neurol 1992; 49: 946-53.
7. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-65.
8. Mann DM, Marcyniuk B, Yates PO, et al. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol 1988; 14: 177-95.
9. Price JL, Ko AI, Wade MJ, et al. Neuron number in the entorhinal cortex and CAI in preclinical Alzheimer's disease. Arch Neurol 2001; 58: 1395-402.
10. Van Hoesen GW, Mesulam MM, Haaxma R. Temporal cortical projections to the olfactory tubercle in the rh monkey. Brain Res 1976; 109: 375-81.
11. Van Hoesen GW, Hyman BT. Hippocampal formation: anatomy and the patterns of patholog Alzheimer's disease. Brain Res 1990; 83: 445-57.
12. Pearson RCA, Esiri MM, Hiorns RW, et al. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. Proc Natl Acad Sci USA 1985; 82: 4531-4.
13. Hof PR, Cox K, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's Disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol 1990; 301: 44-54.
14. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990; 11: 29-37.
15. Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
16. Hof PR, Archin N, Osmand AP, et al. Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report. Acta Neuropathol (Berl) 1993; 86: 215-23.
17. Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999; 56: 1233-9.
18. Terry RD, Masliah E, Hansen LA. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In Terry RD, Katzman R, Bick KL, Sisodia SS, eds. Alzheimer disease, second edition. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 187-206.
19. Selkoe DJ. Alzheimer's disease: a central role for the amyloid. J Neuropathol Exp Neurol 1994; 53: 438-47.
20. Lopez OL, Claassen D. Cerebral amyloid angiopathy in Alzheimer's disease: Clinicopathological correlations. Dementia 1991; 2: 285-90.
21. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999; 402: 533-7.
22. Vassar R, Bennet BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-41.
23. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275: 630-1.
24. Mann DMA, Ivatsubo T, Cairns NJ, et al. Amyloid beta protein deposition in chromosome 14-linked Alzheimer disease: Predominance of A eta 42. Ann Neurol 1996; 40: 149-56.
25. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A-beta-42(43) and A-beta-40 in senile plaques with end specific A-beta monoclonals: Evidence that an initially deposited species as A-beta-42(43). Neuron 1994; 13: 45-53.
26. Citron M, Diehl TS, Gordon G, et al. Evidence that the 42- and 40-amino acid forms of amyloid protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci 1996; 93: 13170-5.
27. Yan SD, Chen X, Fu J. RAGE and amyloid-8 peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-91.
28. Rogers J, Luber-Narod J, Styren SD, et al. Expression of immune system associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988; 9: 339-49.
29. Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286: 2352-5.
30. Mrak RE, Sheng JG, Griffin WST. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995; 26: 816-23.
31. McGeer PL, Rogers J, McGeer EG. Neuroimmune mechanisms in Alzheimer's disease patients. Alzheimer Dis Assoc Disord 1994; 8: 149-58.
32. Griffin WST, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 1989; 86: 7611-5.
33. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-68.
34. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-59.
35. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91.
36. Ohtsubo K, Izumiyama N, Shimada H, et al. Three-dimensional structure of Alzheimer's neurofibrillary tangles of the aged human brain revealed by the quick-freeze, deep-etch and replica method. Neuropathol 1990; 79: 480-5.
37. Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 1963; 22: 629-42.
38. Brion JP, Passrererio H, Nunez J. Immunological detection of tau protein in neurofibrillary tangles of Alzheimer's disease. Arch Biol 1985; 96: 229-35.
39. Lee VM-L, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Ann Rev Neurosci 2001; 24: 1121-59.
40. Conrad C, Andreadis CC, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 41: 277-81.
41. Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and parkinsonism linked to chromosome 17: A new group of tauopathies. Brain Pathology 1998; 8: 387-402.
42. Jahn R, Schiebler W, Quinent C, et al. A 38,000 dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 1985; 82: 4137-41.
43. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlations with cognitive severity. Ann Neurol 1990; 27: 457-64.
44. Zhan S, Beyreuther K, Schmitt H. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neuro-degenerative disorders with dementia. Dementia 1993; 4: 66-74.
45. Masliah E, Terry RD, Alford M, et al. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 1991; 138: 235-46.
46. Masliah E, Ellisman M, Carragher B. Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer's disease. J Neuropathol Exp Neurol 1992; 51: 404-14.
47. Perry G, Kawai M, Tabaton M. Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. J Neurosci 1991; 11: 1748-55.
48. Hirano A, Dembitzer HM, Kurland LT, et al. The fine structure of some intraganglionic alterations, neurofibrillary tangles, granulovacuolar bodies and rod-like structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. J Neuropathol Exp Neurol 1986; 27: 167-82.
49. Goldman JE. The association of actin with Hirano bodies. J Neuropathol Exp Neurol 1983; 42: 146-52.
50. Galloway PG, Perry G, Kosik KS, et al. Hirano bodies contain tau protein. Brain Res 1987; 403: 337-40.
51. Ball MJ, Lo P. Granulovacuolar degeneration in the aging brain and in dementia. J Neuropathol Exp Neurol 1977; 36: 474-87.
52. Price DL, Altschuler RJ, Struble RG, et al. Sequestration of tubulin in neurons in Alzheimer's disease. Brain Res 1986; 385: 305-10.
53. Dickson DW, Ksiezak-Reding H, Davies P, et al. A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments, and tau proteins immunostains granulo-vacuolar degeneration. Acta Neuropathol 1987; 73: 254-8.
54. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990; 237: 197-204.
55. Perry RH, Irving D, Blessed G, et al. Senile dementia of Lewy body type and spectrum of Lewy body disease. Lancet 1989; 13: 1088.
56. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology 1990; 40: 1-8.
57. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report on the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
58. Hansen LA. The Lewy body variant of Alzheimer disease. J Neural Transm Suppl 1997; 51: 83-93.
59. Hamilton RL. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathology 2000; 10: 378-84.
60. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995; 10: 19-45.
61. LaFerla FM, Tinkle BT, Bieberich CJ, et al. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995; 9: 21-30.
62. Mattson MP, Partin J, Begley JG. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 1998; 807: 167-76.
63. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. New Eng J Med 1994; 330: 613-22.
64. Selden N, Geula C, Hersh L, et al. Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience 1994; 3: 621-36.
65. Guo Q, Christakos S, Robinson S, et al. Calbindin D28k blocks the proapoptotic actions of mutant presinilin 1: reduced oxidative stress and preserved nitochondrial function. Proc Natl Acad Sci USA 1998; 95: 3227-32.
66. Whitehouse P, Price DL, Clark AW, et al. Alzheimer's disease: evidence from selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-6.
67. Mesulam M-M. Structure and function of cholinergic pathways in the cerebral cortex, limbic system, basal ganglia, and thalamus of the human brain. In Bloom FE, Kupfer DJ, eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995. p. 135-46.
68. Geula C, Mesulam M-M. Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 1989; 33: 469-81.
69. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
70. Bowen DM, Allen SJ, Benton JS. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983; 41: 266-72.
71. Perry EK, Perry RH, Blessed G, et al. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1.
72. Baskin DS, Browning JL, Pirozzolo FJ, et al. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol 1999; 56: 1121-3.
73. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hupothesis. Exp Neurol 2000; 163: 495-529.
74. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer 11 entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001; 49: 202-13.
75. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 281: 1433-4.
76. DeKosky ST, Ikonomovic MD, Paulin ME, et al. Cognitive, cholinergic, and neuropathologic changes in normal aging, mild cognitive impairment, and mild Alzheimer's disease (Abstract). Neurology 2000; 54 (Suppl 3): A78.
77. Gilmor ML, Erickson JD, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999; 411: 693-704.
78. Tiraboschi P, Hansen LA, Alford M, et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 2000; 55: 1278-83.
79. Schroder H, Zilles K, Luiten PGM, et al. Human cortical neurons contain both nicotinic and muscarinic acetylcholine receptors: an immunocytochemical double-labeling study. Synapse 1989; 4: 319-26.
80. Araujo DM, Lapchak PA, Robitaille Y, et al. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neuroschem 1988; 50: 1914-23.
81. DeKosky ST, Scheff SW, Markesbery WR. Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging. Neurology 1985; 35: 1425-31.
82. Nordber A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain change with aging and dementia. J Neurosci Res 1992; 31: 103-11.
83. Probst A, Cortes R, Ulrich J. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study. Brain Res 1988; 150: 190-201.
84. Flynn DD, Ferrari-DiLeo G, Levey AI, et al. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci 1995; 56: 869-76.
85. Ferrari-DiLeo G, Mash DC, Flynn DD. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer's disease. Mol Chem Neuropathol 1995; 24: 69-91.
86. Nordberg A. Nicotonic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biol Psychiatry 2001; 49: 200-10.
87. Paterson D, Nordberg A. Neural nicotinic receptors in the human brain. Progress in Neurobiology 2000; 61: 75-111.
88. Marutle A, Warpman U, Bognanovic N, et al. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor 670/671 mutation. J Neurochem 1999; 72: 1161-9.
89. Martín-Ruiz CM, Molnar E, Lee M, et al. Alpha4 but not Alpha3 and Alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999; 73: 1635-40.
90. Nordberg A, Amberla K, Shigeta M, et al. Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities. Alzheimer Dis Assoc Disord 1998; 12: 228-37.
91. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992; 13: 747-58.
92. Maelicke A, Schrattenholtz A, Storch A, et al. Noncompetitive agonist at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. J Recept Signal Transduct Res 1995; 15: 333-53.
93. Maelicke A, Schrattenholz A, Samochocki M, et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000; 113: 199-206.
94. Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. Neurol 1989; 39: 355-61.
95. McGeer PL, McGeer EG, Suzuki J, et al. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 1984; 34: 741-5.
96. Beach TG, McGeer EG. Senile plaques, amyloid beta-protein, and acetylcholinesterase fibers: laminar distributors in Alzheimer's disease striate cortex. Acta Neuropathol 1992; 83: 292-9.
97. Ransmayr G, Cervera P, Hirsch EC, et al. Alzheimer's disease: is the decrease of cholinergic innervation of the hippocampus related to intrinsic hippocampal pathology? Neuroscience 1992; 47: 843-51.
98. Zubenko GS, Moosey J, Martinez AJ, et al. A brain regional analysis of morphometric and cholinergic abnormalities in Alzheimer's disease. Arch Neurol 1989; 46: 634-8.
99. Arendt T, Taubert G, Bigl V, et al. Amyloid deposition in the nucleus basalis of Meynert complex, a topographic marker for degenerating cell clusters in Alzheimer's disease. Acta Neuropathol 1988; 75: 226-32.
100. Mann DMA, Yates PO, Marcyniuk B. Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett 1985; 56: 51-5.
101. Harkany T, De Jong GI, Soos K, et al. Beta-amyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Brain Res 1995; 698: 270-4.
102. Harkany T, Lengyel Z, Soos K, et al. Cholinotoxic effects of beta-amyloid (1-42) peptide on cortical projections of the rat nucleus basalis magno-cellularis. Brain Res 1995; 695: 71-5.
103. Zweig R, Ross C, Hedreen JC. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24: 233-42.
104. Halliday GM, McCann HL, Pamphliett R. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathol 1992; 84: 638-50.
105. Mann DMA, Lincoln J, Yates PO, et al. Changes in the monoamine containing neurons of the human CNS in senile dementia. Br J Psychiat 1980; 136: 533-41.
106. Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer's disease neurofibrillary tangles and loss of large neurons. Ann Neurol 1985; 17: 573-7.
107. Cross AJ, Crow TJ, Ferrier IN. Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 1984; 43: 1574-81.
108. Palmer AM, Stratmann GC, Procter AW, et al. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988; 23: 616-20.
109. Mann DMA, Yates PO. Serotonic nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1983; 46: 96-8.
110. Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiat Clin Neurosci 2001; 13: 5-21.
111. Palmer AM, Francis PT, Bowen DM. Catecholaminergic neurones assessed antemortem in Alzheimer's disease. Brain Res 1987; 414: 365-75.
112. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287: 373-92.
113. Marcyniuk B, Mann DMA, Yates PO. The topography of cell loss from locus coeruleus in Alzheimer's disease. J Neurol Sci 1986; 76: 335-45.
114. Bondareff W, Mountjoy CQ, Roth M. Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1981; 1: 783-4.
115. Burke WJ, Park DH, Chung HD, et al. Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease. Brain Res 1990; 537: 83-7.
116. Zubenko G, Moossy J. Major depression in primary dementia: clinical and neuropathological correlates. Arch Neurol 1988; 45: 1182-6.
117. Forstl H, Burns A, Luthert P, et al. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992; 22: 877-84.
118. Chan-Palay V. Depression and dementia in Parkinson's disease: Catecholamine changes in the locus coeruleus -Basis for therapy. Dementia 1991; 2: 7-17.
119. Rinne JO, Rummukainen J, Paljarvi L, et al. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res 1989; 317: 325-32.
120. Victoroff J, Zarow C, Mack WJ, et al. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer's disease. Arch Neurol 1996; 53: 428-34.
121. Ebinger G, Bruyland M, Martin JJ. Distribution of biogenic amines and their catabolies in brains from patients with Alzheimer's disease. J Neurol Sci 1987; 77: 267-83.
122. Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1984; 43: 359-68.
123. Mann DMA, Yates PO, Marcyniuk B. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle-age. J Neurol Neurosurg Psychiatry 1987; 50: 341-4.
124. Proctor AW, Palmer AM, Francis PT, et al. Evidence of glutamatergic denevation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 1988; 50: 790-802.
125. Ikonomovic MD, Mizukami K, Warde D, et al. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp Neurol 1999; 160: 194-204.
126. Chalmers DT, Dewar D, Graham DI, et al. Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci USA 1990; 87: 1352-6.
127. Hyman BT, Van Hoesen GW, Damasio AR. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 1987; 22: 37-40.
128. Palmer AM. Excitatory amino acid neurons and receptors in Alzheimer's disease. In Kozikowski AP, Barrionuevo G, eds. Neurobiology of the NMDA receptor: From chemistry to clinic. New York: VCH Publishers; 1991. p. 203-37.
129. Lowe SL, Francis PT, Procter AW. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 1988; 111: 785-99.
130. Zorumski CF, Isenberg KE. Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry 1991; 148: 162-73.
131. Guidotti I, Corda MC, Wise BC. GABAergic synapses: supramolecular organization and biochemical regulation. Neuropharmacology 1983; 22: 1471-9.
132. Gottfries CG, Frederiksen SO, Heilig M. Neuropeptides and Alzheimer's disease. Eur Neuropsychopharmacol 1995; 5: 491-500.
133. Minthon L, Edvinsson L, Gustafson L. Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Alzheimer Dis Assoc Disord 1996; 10: 197-203.
134. Minton L, Edvinsson L, Gustafson L. Somatostatin and neuropeptide Y in cerebrospinal fluid correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 1997; 8: 232-9.
135. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
136. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405.
137. Miceli G, Colosimo C, Daniele A, et al. Isolated amnesia with slow onset and stable course, without ensuing dementia: MRI and PEr data and a six-year neuropsychological follow-up. Dementia 1996; 7: 104-10.
138. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397-403.
139. Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358: 201-5.
140. Bell-McGinty S, Lopez OL, Meltzer CC, et al. Brain morphologic abnormalities in mild cognitive impairment (Abstract). Neurology 2002; 58 (Suppl 3): S215.
141. Cagnin A, Brooks DJ, Kennedy AM, et al. In vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-7.
142. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145-55.